S25 Update of the HERA trial and the role of 1 year Trastuzumab as adjuvant therapy for breast cancer

作者
Luca Gianni,Aron Goldhirsch,Richard D. Gelber,Evandro de Azambuja,Marion Jennifer Procter,Michael Untch,Ian E. Smith,Christian Jackisch,David Cameron,Susanne Muehlbauer,Bryan Leyland-Jones,Martine J Piccart,Jose M Baselga,R. Bell
出处
期刊:The Breast [Elsevier BV]
卷期号:18: S11-S11 被引量:23
标识
DOI:10.1016/s0960-9776(09)70033-5
摘要

Background: Trastuzumab, a recombinant monoclonal antibody against the HER-2 receptor, has been shown to significantly improve disease-free and overall survival in women with HER-2 positive early breast cancer when given concurrently with or sequentially after chemotherapy. Materials and Methods: HERA is an ongoing international, multicenter, randomised phase III trial comparing one or two years of adjuvant trastuzumab given every three weeks with observation in 5,102 patients with HER-2 positive either node-negative (tumour size 1.0 cm) or nodepositive early breast cancer who had completed locoregional therapy and had received at least four cycles of standard neoadjuvant or adjuvant chemotherapy. Central confirmation of HER-2 positivity and LVEF 55% after completing chemotherapy and radiotherapy were required prior to randomisation. The second planned interim analysis of the 1 yr vs 2 yr trastuzumab comparison in the HERA trial was conducted on October 20, 2008. The Independent Data Monitoring Committee (IDMC) recommended that the study continue as planned without disclosing data on the 2 yr trastuzumab group. In the observation and the 1 yr trastuzumab groups, 827 disease-free survival events (DFS) have been observed at a median follow up of 48.4 months after randomization, and are the subject to the present update. Results: After release of the HERA and the combined B31 and N9831 results in 2005, a protocol amendment allowed for eligible observation patients to receive trastuzumab and data were continuously collected. Out of the 1698 observation patients, there were 885 observation patients who crossed over to trastuzumab. These late starter patients started trastuzumab at a median of 22.8 months (<1−52.7) from randomization. The updated intent-to-treat (ITT) analysis of DFS confirmed a statistically significant benefit in favour of the patients who received 1 yr of trastuzumab following chemotherapy compared with observation (p < 0.0001). Additional analyses to examine the effect of the late start of trastuzumab in the observation group and the influence of the selective crossover on the treatment comparison will be presented. Conclusion: The updated analysis of the HERA trial confirmed the benefit of delivering adjuvant trastuzumab for 1 yr after chemotherapy in women with HER2-positive tumors despite the substantive crossover of observation group patients to active treatment. The HERA study is ongoing and final results including the comparison of 1 yr vs 2 yrs trastuzumab are expected in 2011.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
做猪要开心完成签到,获得积分10
1秒前
1秒前
Carrie发布了新的文献求助10
1秒前
FashionBoy的应助被馒头就辣条采纳,获得10
2秒前
liu关闭了liu的文献求助
2秒前
一叶完成签到 ,获得积分10
3秒前
3秒前
打打的应助被晚风采纳,获得10
3秒前
华仔的应助被爱听歌的寄云采纳,获得10
4秒前
4秒前
4秒前
4秒前
5秒前
qin202569发布了新的文献求助10
5秒前
不穷知识发布了新的文献求助10
5秒前
Crssss的应助被younger采纳,获得10
6秒前
情怀的应助被younger采纳,获得10
6秒前
7秒前
机智小馒头完成签到,获得积分10
8秒前
8秒前
8秒前
落骛发布了新的文献求助10
8秒前
9秒前
buta完成签到,获得积分10
9秒前
大爱人生完成签到 ,获得积分10
9秒前
9秒前
dy发布了新的文献求助10
10秒前
12秒前
pykw的应助被科研通管家采纳,获得10
12秒前
研友_VZG7GZ的应助被罗伯特骚塞采纳,获得10
12秒前
SciGPT的应助被飘逸衣采纳,获得30
12秒前
FashionBoy的应助被科研通管家采纳,获得10
12秒前
wwwww发布了新的文献求助30
12秒前
隐形曼青的应助被科研通管家采纳,获得10
12秒前
Hello的应助被科研通管家采纳,获得10
12秒前
英姑的应助被酷炫的傲芙采纳,获得10
12秒前
orixero的应助被科研通管家采纳,获得10
12秒前
13秒前
李爱国的应助被cwm采纳,获得10
13秒前
null的应助被科研通管家采纳,获得10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178807
求助须知:如何正确求助?哪些是违规求助? 9569558
关于积分的说明 21805222
捐赠科研通 7773974
什么是DOI,文献DOI怎么找? 3432933
关于科研通互助平台的介绍 2556873
邀请新用户注册赠送积分活动 2478593